



# UNITED STATES PATENT AND TRADEMARK OFFICE

ST  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/857,000	09/07/2001	Philippe Clair	19904-012 NAT	7846
34704	7590	05/31/2006	EXAMINER	
BACHMAN & LAPOINTE, P.C. 900 CHAPEL STREET SUITE 1201 NEW HAVEN, CT 06510			KAM, CHIH MIN	
		ART UNIT	PAPER NUMBER	1656

DATE MAILED: 05/31/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/857,000	CLAIR ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Chih-Min Kam	1656	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 11 May 2006.
- 2a) This action is FINAL.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-8 is/are pending in the application.
- 4a) Of the above claim(s) 2,3 and 5-8 is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 1 and 4 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 30 May 2001 is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
  1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                    | Paper No(s)/Mail Date. _____.   |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____. | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
|   | 6) <input type="checkbox"/> Other: _____.                                   |

## **DETAILED ACTION**

### *Election/Restrictions*

1. Applicant's election with traverse of formula (II), SEQ ID NO:11 and brain cancers in the response to restriction requirement filed May 11, 2006 is acknowledged. In, the response, claim 7 has been amended, and a new claim 8 has been added. The traversal is on the ground(s) that the subject matter of invention addresses the problem of the transfer of molecules active in therapy or diagnosis through the hemato-encephalic barrier (HEB), the solution is the use of particular vector peptides such as the vector peptides of formulas (I), (II) or (III) and, more particularly, the peptide SynBl, and such active molecules are used in different treatments applied to different CNS diseases. Thus, the claims are linked to form a single general concept, have in common the same or corresponding technical features, and are not directed to different inventions. Applicants' response has been considered, however, the argument is not found persuasive because the peptides of formulas (I), (II) and (III), which have different structures (e.g., peptides of formula (I) are peptides of antennapedia family, while peptides of formula (II) are peptides of protegrin family, and peptides of formula (III) are peptides of tachyplesin family) and produce different effects in vectoring, do not have in common the same or corresponding structural and technical features. Regarding the diseases, each disease, which has different diagnosis and treatment, is patentably distinct. Accordingly, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept and lack of unity is deemed proper.

Claims 5-8 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim (i.e., claim 5) cannot depend from any other multiple dependent claim,

claim 3. See MPEP § 608.01(n). Accordingly, the claims have not been further treated on the merits. Claims 2-3 are non-elected invention (i.e., formula (I)) and withdrawn from consideration. Therefore, the peptides of formula (II), the amino acid sequence of SEQ ID NO:11 (SynB1) and claims 1 and 4 are examined.

***Oath/Declaration***

2. The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying the application by application number and filing date is required. See MPEP §§ 602.01 and 602.02. The oath or declaration is defective because the oath does not list the foreign priority document, France 98/15074 under 35 U.S.C. 119(a)-(d).

***Informalities***

The disclosure is objected to because of the following informalities:

3. The specification recites amino acid sequences, e.g., at page 31, line 4; page 33, line 4, without providing a sequence identifier, “SEQ ID NO:”. Appropriate correction is required.  
4. Figs 1, 2, 6, 11, 12 and 15 are objected to because some single and double bonds (e.g., C=O) in Figs. 1 and 2 are not aligned properly, and Figs. 6, 11, 12 and 15 contain French in the description. Appropriate correction is required.

***Claim Objections***

5. Claims 1 and 4 are objected to because the claim contains recitation of non-elected inventions, formulas (I) and (III).

***Claim Rejections - 35 USC § 101***

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

6. Claims 1 and 4 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd. v. Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 1 and 4 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling a method of preparing a conjugate of an active substance and a linear peptide of formula (II), which is capable to pass through the hemato-encephalic barrier to reach brain, by covalently coupling the linear peptide with the active substance, wherein the active substance is doxorubicin, dalargin or penicillin, and wherein the linear peptide is SynB1 (RGGRRLSYSRRRFSTSTGR), does not reasonably provide enablement for a method of preparing a medicine of a linear peptide of formula (II), its retro form, or a fragment of at least 5 successive amino acids coupled to an active substance, which is capable to pass through the hemato-encephalic barrier to be used for diagnosis or therapy of a disorder localized in the CNS, wherein the sequence of the linear peptide, the active substance and the disorders are not defined. The specification does not enable a person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

Claims 1 and 4 encompass a method of preparing a medicine of a linear peptide of formula (II) coupled to an active substance, which is capable to pass through the hemato-encephalic barrier to be used for diagnosis or therapy of a disorder localized in the CNS. The specification, however, only discloses cursory conclusions (page 3, line 22-page 4, line 27) without data supporting the findings, which state that a linear peptide derived from an antibiotic peptide having the formula (I), (II) or (III), or moieties of the peptides, can be used to vector one or more active substances to pass through the hemato-encephalic barrier for therapeutic and diagnostic applications. There are no indicia that the present application enables the full scope in view of the use of the linear peptides of formula (II) in vectoring the active substance as discussed in the stated rejection. The present application does not provide sufficient teaching/guidance as to how the full scope of the claims is enabled. The factors considered in determining whether undue experimentation is required, are summarized in In re Wands (858 F2d at 731,737, 8 USPQ2d at 1400,1404 (Fed. Cir.1988)). The factors most relevant to this rejection are the breadth of the claims, the presence or absence of working examples, the state of the prior art and relative skill of those in the art, the predictability or unpredictability of the art, the nature of the art, the amount of direction or guidance presented, and the amount of experimentation necessary.

(1). The breadth of the claims:

The breadth of the claims is broad and encompasses unspecified variants regarding the linear peptides of formula (II), their retro forms or fragments of at least 5 amino acids; the active substance; and the disorders to be diagnosed or treated, which are not adequately described or demonstrated in the specification.

## (2). The absence or presence of working examples:

The specification demonstrates penetration of doxorubicin into brain using doxo-SynB1 and doxo-SMP-3MP-SEQ ID NO:13 (Example 1); penetration of dalargin into brain using dal-SynB1 (Example 2); penetration of doxorubicin into brain using doxo-SynB3 (Example 3); and penetration of penicillin into brain using PNC-SynB1 (PNC, benzylpenicillin; Example 4). The only linear peptide in the formula (II) tested as a vector for transporting is SynB1, and there are no working examples indicating the vectoring effects of various peptides contained in formula (II), their retro forms or fragments, and the treatment of various disorders localized in CNS using these conjugates.

## (3). The state of the prior art and relative skill of those in the art:

The related art has shown the structures of antibiotic peptides such as protegrin and tachyplesin that have disulfide bonds (e.g., references cited at page 4 of the specification). However, the general knowledge and level of the skill in the art do not supplement the omitted description such as identification of various linear peptides of formula (II), their retro forms or fragments that can vector an active substance to pass through the hemato-encephalic barrier to reach brain, thus the specification needs to provide this guidance for enabling for all variants.

## (4). The amount of direction or guidance presented and the quantity of experimentation necessary:

The claimed invention is directed to a method of preparing a medicine of a linear peptide of formula (II) coupled to an active substance, which is capable to pass through the hemato-encephalic barrier to be used for diagnosis or therapy of a disorder localized in the CNS. While the specification demonstrates SynB1 as a vector for transporting doxorubicin, dalargin or

penicillin into brain (Examples 1, 2, 4), there are no working examples indicating the vectoring effects of various peptides contained in formula (II), their retro forms or fragments, and the treatment of various disorders localized in CNS using these conjugates. Furthermore, the specification fails to identify any other linear peptides of formula (II) that have vectoring effect. Moreover, the specification does not provide any specific guidance on the identification of fragments or retro forms of linear peptides of formula (II). Since the specification does not provide sufficient teachings on the identities of active linear peptides of formula (II), it is necessary to carry out undue experimentation to identify the active peptides from formula (II).

(5). Predictability or unpredictability of the art:

As indicated in the previous sections, there is only one linear peptide of formula (II) identified as a vector for transporting some specific active substance into brain. Because the amino acid sequences of formula (II) are highly variable, it is not known whether all the peptides of formula (II) would have the same vectoring effect as SynB1, and it is not readily apparent that one would have been able to a`priori predict the vectoring effect of each peptide of formula (II).

(6). Nature of the Invention

The scope of the claims includes many structural variants, but the specification has not shown how to identify the active peptides from numerous peptide variants or fragments. Thus, the disclosure is not enabling for reasons discussed above.

In summary, the scope of the claim is broad, while the working example does not demonstrate the claimed methods associated with the variants, the teachings in the specification are limited, the sequences of active peptides are unpredictable, therefore, it is necessary to have

additional guidance and to carry out undue experimentation to identify the active peptides that can transport active substances to pass through the hemato-encephalic barrier into brain.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

8. Claims 1 and 4 provide for the use of a linear peptide coupled to an active substance to vector the active substance passing through the hemato-encephalic barrier for diagnosis or therapy of a disorder localized in the CNS, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced. Claims 1 and 4 are also indefinite as to "active substance" and "disorder localized in the CNS", it is not clear what compound the active substance refers to, and what disease the disorder localized in the CNS refers to.
9. Claims 1 and 4 are indefinite because of the use of the term "may be". The term "may be" renders the claim indefinite, it is unclear whether groups b or groups X is identical or different: Claim 4 is included in the rejection because it is dependent on a rejected claim and does not correct the deficiency of the claim from which it depends.
10. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by

"such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949). In the present instance, claim 1 recites the broad recitation "composed of a sequence of at least 5", and the claim also recites "preferably at least 7 successive amino acids of peptides" which is the narrower statement of the range/limitation.

12. Claim 4 is indefinite because of the use of the terms "Aib" and "Abu". The terms "Aib" and "Abu" render the claim indefinite, it is unclear what the term means. A full name should be indicated at the first occurrence.

### *Conclusions*

13. No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr can be reached at 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Chih-Min Kam, Ph. D.  
Patent Examiner



CHIH-MIN KAM  
PATENT EXAMINER

CMK  
May 25, 2006